**Pharma Hemp ®**
**L A B O R A T O R I E S**

**ilac-MRA**

**SLOVENSKA AKREDITACIJA**
SIST EN ISO/IEC 17025
**LP-117**
The results marked by **#** relate to non-accredited activity

# CERTIFICATE OF ANALYSIS No.: 2022-10480

**CLIENT**
Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

**SAMPLE \***
CBD HEMP DERIVED WATER SOLUBLE DROPS 5% -
L-thnnn / green tea

| | | | | | |
|---|---|---|---|---|---|
| Sample condition: | SUITABLE | Work order: | 2022-107109 | Sample received: | 25/11/2022 |
| Sample ID: | 2247054 | Analysis ID: | 2022_267 | Start of analysis: | 25/11/2022 |
| Sample type: | Viscous liquid | Method ID: | PHL_RPC_12C | End of analysis: | 28/11/2022 |
| Batch No.: \* | DW05022329B | Method SOP: | MET-LAB-001-06 | Analyst: | Blaž Janežič |

\* Information provided by the client.

| CANNABINOID PROFILE | | Concentration [% w/w] | Expanded uncertainty [% w/w] | Graphic presentation of relative cannabinoid concentration |
|---|---|---|---|---|
| **CBDV** | - Cannabidivarin | 0.057 | 0.013 | |
| **CBDA** | - Cannabidiolic acid | < LOQ | n/a | |
| **CBGA** | - Cannabigerolic acid | < LOQ | n/a | |
| **CBG** | - Cannabigerol | 0.296 | 0.074 | |
| **CBD** | - Cannabidiol | 5.21 | 0.26 | |
| **THCV** | - Tetrahydrocannabivarin | < LOQ | n/a | |
| **CBN** | - Cannabinol | < LOQ | n/a | |
| **$\Delta^9$-THC** | - $\Delta$-9-Tetrahydrocannabinol | < LOQ | n/a | |
| **$\Delta^8$-THC** | - $\Delta$-8-Tetrahydrocannabinol | < LOQ | n/a | |
| **CBL** | - Cannabicyclol | < LOQ | n/a | |
| **CBC** | - Cannabichromene | < LOQ | n/a | |
| **$\Delta^9$-THCA** | - $\Delta$-9-Tetrahydrocannabinolic acid | < LOQ | n/a | |
| **CBE** | - Cannabielsoin | n/a # | n/a | |
| **CBV** | - Cannabivarin | n/a # | n/a | |
| **CBCA** | - Cannabichromenic acid | n/a # | n/a | |
| **CBT** | - Cannabicitran | n/a # | n/a | |

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

**28/11/2022**

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate